Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

NCT07545603 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma, Grade 1
Follicular Lymphoma, Grade 2
Follicular Lymphoma, Grade 3
Follicular Lymphoma Grade 3A

Interventions

DRUG: XNW5004 tablets

Sponsor

Evopoint Biosciences Inc.